73.55 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||70.50 x 100|
|Ask||76.25 x 100|
|Day's Range||72.20 - 75.50|
|52 Week Range||31.70 - 87.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.50|
- Sarepta Therapeutics (SRTP) faced headwinds as they brought their new drug Exondys 51 to the market in the last two years, but the company and its stock have done very well with great execution on the sales front, and in expanding their drug candidate portfolio. - Investors like to see this kind of diversification as revenue begins to pile up, and the stock has gone from $25 to $80 in less than two years. - Unknown Biotricity (BTCY) is in a similar position, launching their first FDA cleared product and expanding their planned product offerings this year with new medical devices in development.
Foundation Medicine, Inc. today announced that financial results for the company's first quarter ended March 31, 2018 will be released on Wednesday, May 2, 2018. The management team will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m.
Foundation Medicine, Inc. today announced the presentation of new findings at the American Association for Cancer Research Annual Meeting. The data supports the use of both tissue- and blood-based comprehensive genomic profiling to advance personalized cancer care and inform the use of targeted and immunotherapy treatment approaches.
CAMBRIDGE, Mass., April 9, 2018 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Foundation Medicine Inc (NASDAQ:FMI), with a market cap of US$2.64B, often getRead More...
Foundation Medicine, Inc. today announced that FoundationOne CDx™, the first U.S. Food and Drug Administration approved comprehensive genomic profiling assay for all solid tumors incorporating multiple companion diagnostics, is now available in the United States.
NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
In December 2017, Foundation Medicine Inc (NASDAQ:FMI) released its latest earnings announcement, which suggested that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...
Stock Monitor: Miragen Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Foundation Medicine, Inc. (NASDAQ: ...
Foundation Medicine, Inc. today announced that the Centers for Medicare & Medicaid Services issued a final National Coverage Determination for patients who receive next generation sequencing testing with an assay that meets the coverage criteria.
Foundation Medicine, Inc. today announced that Chugai Pharmaceutical Co., Ltd. , one of Japan's leading research-based pharmaceutical companies and a member of the Roche Group, will broaden patient access to Foundation Medicine’s comprehensive genomic profiling services for individuals with advanced cancer.
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle false advertising challenges that the companies had filed against each other under the Lanham Act related to advertising for their respective liquid genomic profiling assays.
Foundation Medicine, Inc. today announced that members of the company's management team will present at Cowen & Company’s 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.m.
The Cambridge, Massachusetts-based company said it had a loss of $1.05 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Foundation Medicine today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year inclu
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Foundation Medicine, Inc. (NASDAQ: FMI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 4:30 PM Eastern ...
After reading Foundation Medicine Inc’s (NASDAQ:FMI) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compareRead More...
Foundation Medicine Inc (NASDAQ: FMI ), a manufacturer of genomic analysis diagnostics for solid and circulating cancer, is uniquely positioned in comprehensive cancer profiling, a Cowen analyst said. ...
Foundation Medicine, Inc. today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.
Foundation Medicine, Inc. and the European Organisation for Research and Treatment of Cancer announced today a collaboration in which Foundation Medicine’s comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC’s Screening Patients for Efficient Clinical Trial Access program.